医学综述
醫學綜述
의학종술
Medical Recapitulate
2015年
17期
3243-3245
,共3页
脑卒中后继发性癫痫%醒脑静%卡马西平%临床疗效%安全性
腦卒中後繼髮性癲癇%醒腦靜%卡馬西平%臨床療效%安全性
뇌졸중후계발성전간%성뇌정%잡마서평%림상료효%안전성
Post stroke epilepsy%Xingnaojing%Carbamazepine%Clinical efficacy%Safety
目的:探讨醒脑静辅助卡马西平治疗脑卒中后继发性癫痫( PSE )的临床疗效及安全性。方法将2010年12月至2013年12月恩施市中心医院收治的80例继发性癫痫患者按照随机数字表法分为两组,各40例。对照组仅给予卡马西平进行治疗,每次0.1 mg,口服,每日3次;观察组在此基础上给予醒脑静进行治疗,20 mL醒脑静注射液与100 mL葡萄糖溶液进行静脉滴注,每日1次。7d为1个疗程,连续治疗4个疗程。比较两组患者的临床疗效,治疗前后痫样放电和累及导联数,生活质量及不良反应发生率。结果观察组总有效率为92.5%(37/40),对照组为70.0%(28/40),差异有统计学意义(P<0.05)。治疗后对照组痫样放电与累及导联数分别为(11.2±4.4) t/180 s、(5.4±1.4)/180s,观察组分别为(6.9±1.3)t/180s、(3.0±0.6)/180s,均较治疗前显著降低,且治疗后观察组上述指标均显著小于对照组( P<0.01)。治疗后观察组生活质量评分显著优于对照组(P<0.01);观察组不良反应发生率和对照组分别为10.0%(4/40)和20.0%(8/40),差异无统计学意义(P>0.05)。结论醒脑静辅助卡马西平治疗继发性癫痫疗效显著,安全性高。
目的:探討醒腦靜輔助卡馬西平治療腦卒中後繼髮性癲癇( PSE )的臨床療效及安全性。方法將2010年12月至2013年12月恩施市中心醫院收治的80例繼髮性癲癇患者按照隨機數字錶法分為兩組,各40例。對照組僅給予卡馬西平進行治療,每次0.1 mg,口服,每日3次;觀察組在此基礎上給予醒腦靜進行治療,20 mL醒腦靜註射液與100 mL葡萄糖溶液進行靜脈滴註,每日1次。7d為1箇療程,連續治療4箇療程。比較兩組患者的臨床療效,治療前後癇樣放電和纍及導聯數,生活質量及不良反應髮生率。結果觀察組總有效率為92.5%(37/40),對照組為70.0%(28/40),差異有統計學意義(P<0.05)。治療後對照組癇樣放電與纍及導聯數分彆為(11.2±4.4) t/180 s、(5.4±1.4)/180s,觀察組分彆為(6.9±1.3)t/180s、(3.0±0.6)/180s,均較治療前顯著降低,且治療後觀察組上述指標均顯著小于對照組( P<0.01)。治療後觀察組生活質量評分顯著優于對照組(P<0.01);觀察組不良反應髮生率和對照組分彆為10.0%(4/40)和20.0%(8/40),差異無統計學意義(P>0.05)。結論醒腦靜輔助卡馬西平治療繼髮性癲癇療效顯著,安全性高。
목적:탐토성뇌정보조잡마서평치료뇌졸중후계발성전간( PSE )적림상료효급안전성。방법장2010년12월지2013년12월은시시중심의원수치적80례계발성전간환자안조수궤수자표법분위량조,각40례。대조조부급여잡마서평진행치료,매차0.1 mg,구복,매일3차;관찰조재차기출상급여성뇌정진행치료,20 mL성뇌정주사액여100 mL포도당용액진행정맥적주,매일1차。7d위1개료정,련속치료4개료정。비교량조환자적림상료효,치료전후간양방전화루급도련수,생활질량급불량반응발생솔。결과관찰조총유효솔위92.5%(37/40),대조조위70.0%(28/40),차이유통계학의의(P<0.05)。치료후대조조간양방전여루급도련수분별위(11.2±4.4) t/180 s、(5.4±1.4)/180s,관찰조분별위(6.9±1.3)t/180s、(3.0±0.6)/180s,균교치료전현저강저,차치료후관찰조상술지표균현저소우대조조( P<0.01)。치료후관찰조생활질량평분현저우우대조조(P<0.01);관찰조불량반응발생솔화대조조분별위10.0%(4/40)화20.0%(8/40),차이무통계학의의(P>0.05)。결론성뇌정보조잡마서평치료계발성전간료효현저,안전성고。
Objective To explore the clinical efficacy and safety of Xingnaojing assisted carbamazepine in the treatment of post stroke epilepsy( PSE) . Methods Total of 80 secondary epilepsy patients admitted to Enshi Center Hospital from Dec. 2010 to Dec. 2010 were randomly divided into two groups:control group(40 cases) receiving carbamazepine treatment(0. 1 mg/time,oral,3 times per day),observation group(40 cases) receiving Xingnaojing( i. v. 20 mL with 100 mL glucose solution) treatment on the basis of the control group′s treatment. The clinical efficacy,epilepsy discharge and involved lead number and quality of life before and after treatment and the incidence of adverse reactions of the two groups were compared. Results The clinical curative effect of the observation group was 92. 5%(37/40),of the control group was 70. 0%(28/40),the differences was statistically significant(P<0. 05). After treatment,epileptiform discharge and the number of involved leads of the control group were (11. 2 ± 4. 4) t/180 s,(5. 4 ± 1. 4)/180 s,of the observation group were (6. 9 ± 1. 3) t/180 s,(3. 0 ± 0. 6)/180 s,which were all significantly lower than before treatment,and the observation group′s data were significantly less than that of the control group after treatment(P<0. 01). After treatment,quality of life of the observation group was significantly better than the control group ( P<0. 01). The incidence of adverse reaction of the observation group and control group were 10. 0%(4/40) and 20. 0%(8/40),the difference was not statistically significant(P >0. 05). Conclusion Xingnaojing assisted carbamazepine treating PSE has obvious therapeutic effect and high safety.